Clinical evaluation of cisplatin sensitivity of germline polymorphisms in neoadjuvant chemotherapy for urothelial cancer Journal Article


Authors: O'Donnell, P. H.; Alanee, S.; Stratton, K. L.; Garcia-Grossman, I. R.; Cao, H.; Ostrovnaya, I.; Plimack, E. R.; Manschreck, C.; Ganshert, C.; Smith, N. D.; Steinberg, G. D.; Vijai, J.; Offit, K.; Stadler, W. M.; Bajorin, D. F.
Article Title: Clinical evaluation of cisplatin sensitivity of germline polymorphisms in neoadjuvant chemotherapy for urothelial cancer
Abstract: Micro-Abstract To identify patients with urothelial cancer most likely to benefit from neoadjuvant chemotherapy, we evaluated germline pharmacogenomic markers for an association with response in 205 patients across 3 institutions. Stage pT0 (26%) and < pT2 (50%) rates were consistent across the respective discovery and replication cohorts. Despite the large effects for 3 polymorphisms in the discovery set, none were associated with achievement of pT0 or < pT2 on replication. Multi-institutional efforts are feasible and will be necessary to achieve advances in urothelial cancer precision medicine. © 2016 Elsevier Inc.
Keywords: bladder cancer; pharmacogenomics; precision medicine; treatment response prediction
Journal Title: Clinical Genitourinary Cancer
Volume: 14
Issue: 6
ISSN: 1558-7673
Publisher: Elsevier Inc.  
Date Published: 2016-12-01
Start Page: 511
End Page: 517
Language: English
DOI: 10.1016/j.clgc.2016.03.006
PROVIDER: scopus
PMCID: PMC5018246
PUBMED: 27150640
DOI/URL:
Notes: Article -- Export Date: 6 December 2016 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Dean Bajorin
    423 Bajorin
  2. Kenneth Offit
    521 Offit
  3. Vijai Joseph
    120 Joseph
  4. Shaheen Riadh Alanee
    11 Alanee